ArticleCancer research2017
Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 89 citations in OpenAlex.
- Integrin-Defined Plasma Extracellular Vesicles for Early Breast Cancer Detection and Bone Metastasis Association.ACS applied nano materials · 2026Article
- Targeting Matrix Stiffness and Mechanotransduction in Breast Cancer: Implications for Emerging Therapies.International journal of molecular sciences · 2026Review
- Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer.Oncology research · 2026Review
- Circulating tumor cells in breast cancer bone metastasis: mechanisms, clinical relevance, and future directions.Cell death discovery · 2025Review
- Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy.Discover oncology · 2025Review
- Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications.International journal of molecular sciences · 2025Review
- Invasion and metastasis in cancer: molecular insights and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- A machine learning-based investigation of integrin expression patterns in cancer and metastasis.Scientific reports · 2025Article
- Article
- Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.Breast cancer research : BCR · 2024Article
- Nanotheranostics in Breast Cancer Bone Metastasis: Advanced Research Progress and Future Perspectives.Pharmaceutics · 2024Review
- Bone targeted nano-drug and nano-delivery.Bone research · 2024Review
- Lymphotoxin-β promotes breast cancer bone metastasis colonization and osteolytic outgrowth.Nature cell biology · 2024Article
- The Role of αvβ3 Integrin in Cancer Therapy Resistance.Biomedicines · 2024Review
- Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.International journal of nanomedicine · 2024Review
- Design of Nanodrug Delivery Systems for Tumor Bone Metastasis.Current pharmaceutical design · 2024Review
- Hypoxia-cleavable and specific targeted nanomedicine delivers epigenetic drugs for enhanced treatment of breast cancer and bone metastasis.Journal of nanobiotechnology · 2023Article
- Nanomaterial-assisted theranosis of bone diseases.Bioactive materials · 2023Review
- Review
- The role of integrin family in bone metabolism and tumor bone metastasis.Cell death discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Michael H RossDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Alison K EsserDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Gregory C FoxDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Anne H SchmiederDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Xiaoxia YangDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Grace HuDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Dipanjan PanDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Champaign, Illinois.
Xinming SuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Yalin XuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Deborah V NovackDepartment of Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, Missouri.
Thomas WalshDepartment of Surgery, Division of Public Health Sciences, St. Louis Breast Tissue Registry, Washington University School of Medicine, St. Louis, Missouri.
Graham A ColditzDepartment of Surgery, Division of Public Health Sciences, St. Louis Breast Tissue Registry, Washington University School of Medicine, St. Louis, Missouri.
Gabriel H LukaszewiczDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Elizabeth CordellDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Joshua NovackDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
James A J FitzpatrickDepartments of Cell Biology & Physiology and Neuroscience, Washington University Center for Cellular Imaging, Washington University School of Medicine, St. Louis, Missouri.
David L WaningDepartment of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Khalid S MohammadDepartment of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana.
Theresa A GuiseDepartment of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana.
Gregory M LanzaDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Katherine N WeilbaecherDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri. kweilbae@wustl.edu.
Washington University in St. Louis · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MNATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8MRole of Inflammation in Tax-mediated TumorigenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · PI Lee Ratner · 2003 to 2026
$44.8MWU-MDACC Inter-Institutional Molecular Imaging CenterP50CA094056 · NCI · WASHINGTON UNIVERSITY · PI PIWNICA-WORMS, DAVID · 2002 to 2016
$26.3MTRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4MProject 2 - Radiation-Induced Treatment of Multiple Myeloma using NanoparticlesU54CA199092 · NCI · WASHINGTON UNIVERSITY · PI DIPERSIO, JOHN F. · 2015 to 2019
$11.5MThe Role of the Osteoblast Secretome in Bone FormationP30AR057235 · NIAMS · WASHINGTON UNIVERSITY · PI SILVA, MATTHEW J · 2009 to 2018
$5.7MMOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7MSkeletal Disorders Training ProgramT32AR060719 · NIAMS · WASHINGTON UNIVERSITY · PI Roberto Civitelli · 2011 to 2026
$4.6MTheranostic Approach to Asthma Using Anti-Angiogenic NanomedicineR01HL113392 · NHLBI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, WAGNER, ELIZABETH · 2012 to 2016
$3.3MROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASISR01CA097250 · NCI · WASHINGTON UNIVERSITY · PI WEILBAECHER, KATHERINE NELSON · 2003 to 2014
$3.3MOVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPYR01CA216840 · NCI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, WEILBAECHER, KATHERINE NELSON · 2018 to 2022
$3.1MNCI NIH HHS P01 CA100730NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA094056NCI NIH HHS R01 CA069158NCI NIH HHS R01 CA097250NCI NIH HHS R01 CA154737NCI NIH HHS R01 CA216840NCI NIH HHS R29 CA069158NCI NIH HHS R56 CA097250NCI NIH HHS T32 CA113275NCI NIH HHS U01 CA143057NCI NIH HHS U54 CA199092NCRR NIH HHS S10 RR027552NHLBI NIH HHS R01 HL113392NHLBI NIH HHS R01 HL122471NHLBI NIH HHS R42 HL112518NIAMS NIH HHS P30 AR057235NIAMS NIH HHS T32 AR060719NIGMS NIH HHS T32 GM007067NIGMS NIH HHS T32 GM007200NINDS NIH HHS R24 NS086741
Abstract
Bone metastases occur in approximately 70% of metastatic breast cancer patients, often leading to skeletal injuries. Current treatments are mainly palliative and underscore the unmet clinical need for improved therapies. In this study, we provide preclinical evidence for an antimetastatic therapy based on targeting integrin β3 (β3), which is selectively induced on breast cancer cells in bone by the local bone microenvironment. In a preclinical model of breast cancer, β3 was strongly expressed on bone metastatic cancer cells, but not primary mammary tumors or visceral metastases. In tumor tissue from breast cancer patients, β3 was significantly elevated on bone metastases relative to primary tumors from the same patient (
Indexed as
Xenograft Model Antitumor AssaysAnimalsBone NeoplasmsBreast NeoplasmsCell Line, TumorDocetaxelFemaleGene Expression Regulation, NeoplasticHumansIntegrin alphaVbeta3Integrin beta3Mice, Inbred BALB CMice, Inbred C57BLMice, NudeMolecular Targeted TherapyNanoparticlesDocetaxelIntegrin alphaVbeta3Integrin beta3TaxoidsTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.